Aurobindo Pharma’s arm gets marketing authorization for Dyrupeg

07 Apr 2025 Evaluate

Aurobindo Pharma’s wholly owned step-down subsidiary -- CuraTeQ Biologics s.r.o. has received marketing authorization from European Commission (EC) in the European Union (EU) for Dyrupeg, a pegylated filgrastim biosimilar. 

Earlier in January 2025, the Committee for Medicinal Products (CHMP) of European Medicines Agency had adopted positive opinion recommending the approval of Dyrupeg.

Aurobindo Pharma is engaged in manufacturing pharmaceutical products. It offers active pharmaceutical ingredients, intermediates and generic formulations like astemizole, domeperidone and omeprazole; anti-infective, oral and sterile antibiotics, pain management and osteoporosis segments.

Aurobindo Pharma Share Price

1217.85 -39.75 (-3.16%)
25-Apr-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1786.85
Dr. Reddys Lab 1173.55
Cipla 1525.50
Lupin 2018.35
Zydus Lifesciences 859.10
View more..
© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.
×
Please wait your portfolio is updating...